Aardvark Therapeutics, Inc.
AARD
$9.35
$1.0612.79%
| Weiss Ratings | AARD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | AARD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | AARD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | AARD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 1.19% | |||
| 30-Day Total Return | -37.25% | |||
| 60-Day Total Return | -- | |||
| 90-Day Total Return | -- | |||
| Year to Date Total Return | -34.66% | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -57.66% | |||
| 52-Week Low % Change | 22.09% | |||
| Price | AARD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $19.58 | |||
| 52-Week Low Price | $6.79 | |||
| 52-Week Low Price (Date) | Mar 31, 2025 | |||
| 52-Week High Price (Date) | Feb 20, 2025 | |||
| Valuation | AARD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 177.28M | |||
| Enterprise Value | 231.15M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.49 | |||
| Earnings Per Share Growth | 167.15% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -0.73 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $9.35 | |||
| Enterprise Value/EBITDA (TTM) | -45.43 | |||
| Enterprise Value/EBIT | -14.85 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | AARD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 3.99M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AARD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 225 7696 | |||
| Address | 4370 La Jolla Village Drive San Diego, CA 92122 | |||
| Website | aardvarktherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2017 | |||
| Profitability | AARD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | AARD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -- | |||
| Return on Equity | -- | |||
| Income Statement | AARD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -5.09M | |||
| EBIT (TTM) | -15.57M | |||
| Net Income (TTM) | -13.85M | |||
| Net Income Avl. to Common (TTM) | -13.85M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -98.29% | |||
| EPS Diluted (TTM) | -3.49 | |||
| EPS Diluted Growth (Q YOY) | -97.09% | |||
| Balance Sheet | AARD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 82.36M | |||
| Cash Per Share (Q) | $20.66 | |||
| Total Current Assets (Q) | 82.67M | |||
| Total Preferred Equity (Q) | 126.76 | |||
| Total Equity (Q) | 80.58M | |||
| Current Ratio (Q) | 31.649 | |||
| Book Value Per Share (Q) | -$11.38 | |||
| Total Assets (Q) | 83.74M | |||
| Total Current Liabilities (Q) | 2.61M | |||
| Total Debt (Q) | 868.00K | |||
| Total Liabilities (Q) | 3.16M | |||
| Total Common Equity (Q) | -46.17M | |||
| Cash Flow | AARD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -103.00K | |||
| Cash from Financing (TTM) | 83.01M | |||
| Net Change in Cash (TTM) | 71.39M | |||
| Levered Free Cash Flow (TTM) | -5.42M | |||
| Cash from Operations (TTM) | -11.52M | |||
